Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study

American Journal of Ophthalmology

Volumn 164, Issue , 2016, Pages 128-136.e1

  Ting, Daniel Shu Wei ^a,b,c   Ng, Wei Yan ^a   Ng, Si Rui ^a   Tan, Shu Pei ^b   Yeo, Ian Yew San ^a,b,c   Mathur, Ranjana ^a,b,c   Chan, Choi Mun ^a   Tan, Anna Cheng Sim ^a   Tan, Gavin Siew Wei ^a,b,c   Wong, Tien Yin ^a,b,c   Cheung, Chui Ming Gemmy ^a,b,c  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CHOROIDAL THICKNESS; COHORT ANALYSIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; POLYPS; RISK FACTOR; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHOROID; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; POLYPS; PROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84956677857     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.12.024     Document Type: Article

References (42)

1. 1 Wong, T.Y., Loon, S.C., Saw, S.M., The epidemiology of age related eye diseases in Asia. Br J Ophthalmol 90:4 (2006), 506–511.
2. 2 National Advisory Eye Council, Vision Research - A National Plan: 1999-2003, Vol. 1: A Report of the National Advisory Eye Council. NIH publication 98–4120, 1999, National Institutes of Health, Bethesda, MD.
3. 3 Wong, W.L., Su, X., Li, X., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:2 (2014), e106–e116.
4. 4 Group, C.R., Martin, D.F., Maguire, M.G., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:20 (2011), 1897–1908.
5. 5 Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:14 (2006), 1432–1444.
6. 6 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:14 (2006), 1419–1431.
7. 7 Cheung, C.M., Li, X., Mathur, R., et al. A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy. PLoS One, 9(6), 2014, e101057.
8. 8 Cheung, C.M., Bhargava, M., Xiang, L., et al. Six-month visual prognosis in eyes with submacular hemorrhage secondary to age-related macular degeneration or polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 251:1 (2013), 19–25.
9. 9 Cheung, C.M., Bhargava, M., Laude, A., et al. Asian age-related macular degeneration phenotyping study: rationale, design and protocol of a prospective cohort study. Clin Experiment Ophthalmol 40:7 (2012), 727–735.
10. 10 Gemmy Cheung, C.M., Yeo, I., Li, X., et al. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am J Ophthalmol 155:2 (2013), 295–304.e291.
11. 11 Koizumi, H., Kano, M., Yamamoto, A., et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159:4 (2015), 627–633.
12. 12 Saint-Geniez, M., Maldonado, A.E., D'Amore, P.A., VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 47:7 (2006), 3135–3142.
13. 13 Maharaj, A.S., Saint-Geniez, M., Maldonado, A.E., D'Amore, P.A., Vascular endothelial growth factor localization in the adult. Am J Pathol 168:2 (2006), 639–648.
14. 14 Grunwald, J.E., Pistilli, M., Ying, G.S., et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 122:4 (2015), 809–816.
15. 15 Grunwald, J.E., Daniel, E., Huang, J., et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:1 (2014), 150–161.
16. 16 IVAN Study Investigators, Chakravarthy, U., Harding, S.P., et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:7 (2012), 1399–1411.
17. 17 Busbee, B.G., Ho, A.C., Brown, D.M., et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120:5 (2013), 1046–1056.
18. 18 Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A.E., D'Amore, P.A., An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 106:44 (2009), 18751–18756.
19. 19 Yamazaki, T., Koizumi, H., Yamagishi, T., Kinoshita, S., Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119:8 (2012), 1621–1627.
20. 20 Maruko, I., Iida, T., Sugano, Y., Saito, M., Sekiryu, T., Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:4 (2011), 594–603.e591.
21. 21 Ogasawara, M., Maruko, I., Sugano, Y., Ojima, A., Sekiryu, T., Iida, T., [Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration]. Nihon Ganka Gakkai Zasshi 116:7 (2012), 643–649.
22. 22 Ellabban, A.A., Tsujikawa, A., Ogino, K., et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 6 (2012), 837–844.
23. 23 Koizumi, H., Yamagishi, T., Yamazaki, T., Kawasaki, R., Kinoshita, S., Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 249:8 (2011), 1123–1128.
24. 24 Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 109:9 (1991), 1220–1231.
25. 25 Japanese Study Group of Polypoidal Choroidal Vasculopathy, [Criteria for diagnosis of polypoidal choroidal vasculopathy]. Nihon Ganka Gakkai Zasshi 109:7 (2005), 417–427.
26. 26 Cheung, C.M., Laude, A., Wong, W., et al. Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified everest criteria. Retina 35:7 (2015), 1375–1380.
27. 27 Cheung, C.M., Lai, T.Y., Chen, S.J., et al. Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy. Retina 34:12 (2014), 2397–2406.
28. 28 Cheung, C.M., Loh, B.K., Li, X., et al. Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization. Acta Ophthalmol 91:7 (2013), e580–e581.
29. 29 Margolis, R., Spaide, R.F., A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 147:5 (2009), 811–815.
30. 30 Boey, P.Y., Tay, W.T., Lamoureux, E., et al. C-reactive protein and age-related macular degeneration and cataract: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci 51:4 (2010), 1880–1885.
31. 31 Razavi, S., Souied, E.H., Darvizeh, F., Querques, G., Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol 160:5 (2015), 1006–1013.
32. 32 Sizmaz, S., Kucukerdonmez, C., Kal, A., Pinarci, E.Y., Canan, H., Yilmaz, G., Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab. Eur J Ophthalmol 24:6 (2014), 904–910.
33. 33 Comyn, O., Heng, L.Z., Ikeji, F., et al. Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema. Invest Ophthalmol Vis Sci 53:12 (2012), 7754–7759.
34. 34 Thornton, J., Edwards, R., Mitchell, P., Harrison, R.A., Buchan, I., Kelly, S.P., Smoking and age-related macular degeneration: a review of association. Eye (Lond) 19:9 (2005), 935–944.
35. 35 Sizmaz, S., Kucukerdonmez, C., Pinarci, E.Y., Karalezli, A., Canan, H., Yilmaz, G., The effect of smoking on choroidal thickness measured by optical coherence tomography. Br J Ophthalmol 97:5 (2013), 601–604.
36. 36 Ulas, F., Celik, F., Dogan, U., Celebi, S., Effect of smoking on choroidal thickness in healthy smokers. Curr Eye Res 39:5 (2014), 504–511.
37. 37 Dervisogullari, M.S., Totan, Y., Tenlik, A., Yuce, A., Effects of cigarette smoking on choroidal and retinal thickness and ocular pulse amplitude. Cutan Ocul Toxicol 34:3 (2015), 217–221.
38. 38 Seddon, J.M., Cote, J., Davis, N., Rosner, B., Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 121:6 (2003), 785–792.
39. 39 Cheung, C.M., Wong, T.Y., Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. J Intern Med 276:2 (2014), 140–153.
40. 40 Maruko, I., Iida, T., Oyamada, H., Sugano, Y., Ojima, A., Sekiryu, T., Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. Am J Ophthalmol 156:3 (2013), 548–556.
41. 41 Ahn, S.J., Woo, S.J., Park, K.H., Retinal and choroidal changes with severe hypertension and their association with visual outcome. Invest Ophthalmol Vis Sci 55:12 (2014), 7775–7785.
42. 42 Wong, I.Y., Wong, R.L., Zhao, P., Lai, W.W., Choroidal thickness in relation to hypercholesterolemia on enhanced depth imaging optical coherence tomography. Retina 33:2 (2013), 423–428.